Home » Authors » Douglas Merrill

Articles by Douglas Merrill

Graffinity Raises EUR15M In Third Round For Discovery Programs

Feb. 23, 2004

By Douglas Merrill

Graffinity Raises EUR15M In Third Round For Discovery Programs

Feb. 23, 2004

By Douglas Merrill

Advancements In SiRNA Spur Strategy Change For Atugen

Feb. 11, 2004

By Douglas Merrill

Advancements In SiRNA Spur Strategy Change For Atugen

Feb. 11, 2004

By Douglas Merrill

Dissent With Partner Spurs Cutbacks At Micromet AG

Feb. 4, 2004

By Douglas Merrill

Dissent With Partner Spurs Cutbacks At Micromet AG

Feb. 4, 2004

By Douglas Merrill

Two German Kinase Companies Merge, Bring In EUR11M Financing

Jan. 28, 2004

By Douglas Merrill

MUNICH, Germany - Two young Munich biotechnology companies - Nadag AG and Sireen AG - merged to form Sirenade Pharmaceuticals AG, which will focus on oncology and central nervous system conditions. (BioWorld International)

Two German Kinase Companies Merge, Bring In EUR11M Financing

Jan. 28, 2004

By Douglas Merrill

MUNICH, Germany - Two young Munich biotechnology companies - Nadag AG and Sireen AG - merged to form Sirenade Pharmaceuticals AG, which will focus on oncology and central nervous system conditions. (BioWorld International)

Altana, Aventis File For Alvesco Approval In Persistent Asthma

Dec. 31, 2003

By Douglas Merrill

Altana, Aventis File For Alvesco Approval In Persistent Asthma

Dec. 31, 2003

By Douglas Merrill

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...